Foghorn Therapeutics (FHTX) Revenue (2020 - 2026)

Foghorn Therapeutics' Revenue history runs 7 years deep, the most recent figure standing at $3.3 million for Q1 2026.

• In Q1 2026, Revenue fell 45.11% year-over-year to $3.3 million; the TTM figure through Mar 2026 stood at $28.2 million (up 20.08% YoY), while the FY2025 annual figure was $30.9 million, up 36.75% from the prior year.
• Revenue was $3.3 million for Q1 2026 at Foghorn Therapeutics, down from $9.2 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $17.5 million in Q3 2023 to a low of $2.9 million in Q4 2024.
• Historically, Revenue has averaged $6.5 million across 5 years, with a median of $5.8 million in 2023.
• The sharpest annual moves came in 2022 and 2024: Revenue soared 16080.49% in 2022, then slumped 55.33% in 2024.
• A 5-year view of Revenue shows it stood at $4.2 million in 2022, then soared by 37.88% to $5.8 million in 2023, then tumbled by 50.49% to $2.9 million in 2024, then soared by 223.77% to $9.2 million in 2025, then plunged by 64.67% to $3.3 million in 2026.
• The last three Revenue figures came in at $3.3 million (Q1 2026), $9.2 million (Q4 2025), and $8.2 million (Q3 2025), per Business Quant data.